CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 164 filers reported holding CLOVIS ONCOLOGY INC in Q4 2020. The put-call ratio across all filers is 1.33 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $518 | – | 16,795 | +6618.0% | 0.08% | – |
| Q4 2022 | $0 | – | 250 | 0.0% | 0.00% | – |
| Q3 2022 | $0 | – | 250 | 0.0% | 0.00% | – |
| Q2 2022 | $0 | -100.0% | 250 | 0.0% | 0.00% | – |
| Q1 2022 | $1,000 | 0.0% | 250 | 0.0% | 0.00% | – |
| Q4 2021 | $1,000 | 0.0% | 250 | 0.0% | 0.00% | – |
| Q3 2021 | $1,000 | 0.0% | 250 | 0.0% | 0.00% | – |
| Q2 2021 | $1,000 | -50.0% | 250 | 0.0% | 0.00% | – |
| Q1 2021 | $2,000 | +100.0% | 250 | 0.0% | 0.00% | – |
| Q4 2020 | $1,000 | 0.0% | 250 | 0.0% | 0.00% | – |
| Q3 2020 | $1,000 | -50.0% | 250 | 0.0% | 0.00% | – |
| Q2 2020 | $2,000 | 0.0% | 250 | 0.0% | 0.00% | – |
| Q1 2020 | $2,000 | -33.3% | 250 | 0.0% | 0.00% | -100.0% |
| Q4 2019 | $3,000 | +200.0% | 250 | 0.0% | 0.00% | – |
| Q3 2019 | $1,000 | -75.0% | 250 | 0.0% | 0.00% | -100.0% |
| Q4 2018 | $4,000 | -42.9% | 250 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $7,000 | – | 250 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 407,416 | $14,259,560,000 | 8.34% |
| Palo Alto Investors LP | 3,547,719 | $124,170,000 | 6.91% |
| Antipodean Advisors LLC | 1,268,658 | $44,403,000 | 6.48% |
| Redmile Group, LLC | 1,795,936 | $62,858,000 | 4.70% |
| HealthCor Management, L.P. | 1,525,000 | $53,375,000 | 3.24% |
| PointState Capital LP | 3,503,900 | $122,637,000 | 3.12% |
| NEA Management Company, LLC | 1,139,890 | $39,896,000 | 2.54% |
| CLIFTON PARK CAPITAL MANAGEMENT, LLC | 612,500 | $21,438,000 | 2.44% |
| PFM Health Sciences, LP | 2,078,440 | $72,745,000 | 2.21% |
| Partner Investment Management, L.P. | 35,300 | $1,236,000 | 2.03% |